Iambic Therapeutics, Inc

Iambic Therapeutics, Inc develops AI-driven platforms for the discovery of novel medicines, combining physics-informed machine learning with high-throughput experimental automation to design, synthesize and test drug candidates. Its technical work spans chemical space exploration, structure prediction and molecular modelling, and generative chemistry. Two proprietary technologies underpin the approach: NeuralPLexer, used for structure prediction and molecular modelling, and Enchant, used for generative chemistry; both are also leveraged in partnerships with pharmaceutical companies.

The platform has produced multiple new drug candidates delivered to human clinical trials across several target classes and mechanisms of action. The internal pipeline includes IAM1363, a HER2 inhibitor in Phase 1/1b studies; a selective dual CDK2/4 inhibitor programme for cancer indications; and a programme targeting novel mechanisms including allosteric inhibition of KIF18A. These assets are described as potential best-in-class and first-in-class clinical candidates.

The company operates across the biotechnology and pharmaceutical sectors, with work concentrated in drug discovery and development and in oncology. Further details are available at https://iambic.ai/.